Therapies in the pipeline for small-cell lung cancer.

about

The loss-of-function of DNA methyltransferase 1 by siRNA impairs the growth of non-small cell lung cancer with alleviated side effects via reactivation of RASSF1A and APC in vitro and vivo.Modeling small cell lung cancer (SCLC) biology through deterministic and stochastic mathematical models.

P2860

Q41708839-91BB7148-D31A-4F2A-B19F-BB36DBE34259 Q55110585-CB6CCF03-0E76-4FEB-AC57-716630C95678

P2860

Therapies in the pipeline for small-cell lung cancer.

Item

http://www.wikidata.org/entity/Q38871386

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Therapies in the pipeline for small-cell lung cancer.

@en

type

Item

label

Therapies in the pipeline for small-cell lung cancer.

@en

prefLabel

Therapies in the pipeline for small-cell lung cancer.

@en

P1476

Therapies in the pipeline for small-cell lung cancer

@en

P2093

Aidalena Abidin

http://www.w3.org/2001/XMLSchema#string

Giannis Mountzios

http://www.w3.org/2001/XMLSchema#string

Ourania Romanidou

http://www.w3.org/2001/XMLSchema#string

P2860

MGMT gene silencing and benefit from temozolomide in glioblastoma.

Cancer statistics, 2015

Pretreatment prognostic factors and scoring system in 407 small-cell lung cancer patients

Pharmacogenomic approach to identify drug sensitivity in small-cell lung cancer

Hallmarks of 'BRCAness' in sporadic cancers

Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer.

Phase II trial of second-line bendamustine chemotherapy in relapsed small cell lung cancer patients.

Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer.

Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301.

Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124.

P304

37-48

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/BMB/LDW022

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

119

http://www.w3.org/2001/XMLSchema#string

P50

Floriana Morgillo

Raffaele Califano

Martina Imbimbo

P577

2016-06-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27325208

http://www.w3.org/2001/XMLSchema#string

Therapies in the pipeline for small-cell lung cancer.

about

P2860

P2860

Therapies in the pipeline for small-cell lung cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698